All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 28, 2023
BioWorldBioWorld MedTechBioWorld AsiaBioWorld Science

BioWorld

  • EU flag, pills, syringe

    Otsuka’s schizophrenia drug filing U-turn amongst latest CHMP announcements

    Otsuka Pharmaceutical Co. Ltd. has gone back on efforts to get its medicine, Asimtufii (aripiprazole), a long-acting maintenance treatment for schizophrenia, approved in...
More in BioWorld

BioWorld MedTech

  • tissium.jpg

    Tissium raises $54M for launch of programmable products for tissue reconstruction

    Tissium SA reported the close of a series D funding round, raising $54 million from investors both new – such as Mérieux Développement SAS – and long-term, including Cathay...
More in BioWorld MedTech

BioWorld Science

  • Endosome

    Experimental painkiller blocks GPCR signaling inside the cell

    Researchers have developed a new highly effective therapeutic for pain relief by altering the chemical properties of an antinausea drug, netupitant. The modified drug is...
More in BioWorld Science

BioWorld Asia

  • Huang Baohua, founder and CEO, Coherent Biopharma

    Coherent Biopharma nets $100M in financing for Bi-XDC drugs

    Coherent Biopharma Co. Ltd. raised $100 million in series B and B+ financing rounds to step up its efforts to develop its bi-targeting ligand-drug conjugate (Bi-XDC) drugs...
More in BioWorld Asia

BioWorld Insider Podcast

Better times ahead for the biopharma sector? Could be, the new numbers say. Karen Carey, BioWorld’s managing editor and senior data analyst, and Tim Shannon, a general partner at Canaan, look at first quarter numbers and survey the big picture.
Listen now
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing